Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome?
Floppy infant module
Neonatal neurological examination
Newborn screening
SMA
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
received:
17
01
2024
accepted:
26
03
2024
revised:
12
03
2024
medline:
18
4
2024
pubmed:
18
4
2024
entrez:
18
4
2024
Statut:
aheadofprint
Résumé
Neonatal screening for SMA has allowed the identification of infants who may present with early clinical signs. Our aim was to establish whether the presence and the severity of early clinical signs have an effect on the development of motor milestones. Infants identified through newborn screening were prospectively assessed using a structured neonatal neurological examination and an additional module developed for the assessment of floppy infants. As part of the follow-up, all infants were assessed using the HINE-2 to establish developmental milestones. Only infants with at least 24 months of follow-up were included. Normal early neurological examination (n = 11) was associated with independent walking before the age of 18 months while infants with early clinical signs of SMA (n = 4) did not achieve ambulation (duration follow-up 33.2 months). Paucisymptomatic patients (n = 3) achieved ambulation, one before the age of 18 months and the other 2 between 22 and 24 months. Conclusion: Our findings suggest that early clinical signs may contribute to predict motor milestones development. What is Known: • There is increasing evidence of heterogeneity among the SMA newborns identified via NBS. • The proposed nosology describes a clinically silent disease, an intermediate category ('paucisymptomatic') and 'symptomatic SMA'. What is New: • The presence of minimal clinical signs at birth does not prevent the possibility to achieve independent walking but this may occur with some delay. • The combination of genotype at SMN locus and clinical evaluation may better predict the possibility to achieve milestones.
Identifiants
pubmed: 38634892
doi: 10.1007/s00431-024-05546-y
pii: 10.1007/s00431-024-05546-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Dangouloff T, Vrscaj E, Servais L, Osredkar D, Group SNWS (2021) Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscul Disord 31:574–582
doi: 10.1016/j.nmd.2021.03.007
pubmed: 33985857
Finkel RS, Benatar M (2022) Pre-symptomatic spinal muscular atrophy: a proposed nosology. Brain 145:2247–2249
doi: 10.1093/brain/awac125
pubmed: 35429273
Pane M, Donati MA, Cutrona C, De Sanctis R, Pirinu M, Coratti G, Ricci M, Palermo C, Berti B, Leone D, Ticci C, Sacchini M, Cerboneschi M, Capasso A, Cicala G, Pera MC, Bravetti C, Abiusi E, Vaisfeld A, Vento G, Tiziano FD, Mercuri E (2022) Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. Eur J Pediatr 181:2821–2829
doi: 10.1007/s00431-022-04470-3
pubmed: 35522315
pmcid: 9192449
Crawford TO, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, Kirschner J et al (2023) Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve 68:157–170
doi: 10.1002/mus.27853
pubmed: 37409780
Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, Shieh PB, Kavanagh S, Wigderson M, Tauscher-Wisniewski S, McGill BE, Macek TA (2022) Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med 28(7):1390–1397. https://doi.org/10.1038/s41591-022-01867-3 . Epub 2022 Jun 17. PMID: 35715567; PMCID: PMC9205287
doi: 10.1038/s41591-022-01867-3
pubmed: 35715567
pmcid: 9205287
Kariyawasam DS, D’Silva AM, Sampaio H, Briggs N, Herbert K, Wiley V, Farrar MA (2023) Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study. Lancet Child Adolesc Health 7:159–170
doi: 10.1016/S2352-4642(22)00342-X
pubmed: 36669516
Cutrona C, Pede E, De Sanctis R, Coratti G, Tiberi E, Luciano R, Pera MC, Velli C, Capasso A, Vento G, Romeo DM, Pane M, Mercuri E (2022) Assessing floppy infants: a new module. Eur J Pediatr 181:2771–2778
doi: 10.1007/s00431-022-04476-x
pubmed: 35504981
pmcid: 9192404
Haataja L, Mercuri E, Regev R, Cowan F, Rutherford M, Dubowitz V, Dubowitz L (1999) Optimality score for the neurologic examination of the infant at 12 and 18 months of age. J Pediatr 135:153–161
doi: 10.1016/S0022-3476(99)70016-8
pubmed: 10431108
Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS, Group CS (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625–635
doi: 10.1056/NEJMoa1710504
pubmed: 29443664
Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, Corti S, Daron A, Deconinck N, Servais L, Straub V, Ouyang H, Chand D, Tauscher-Wisniewski S, Mendonca N, Lavrov A, Group SV-Es (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20:832–841
doi: 10.1016/S1474-4422(21)00251-9
pubmed: 34536405
Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, Reash NF, Iammarino MA, Church KR, Kleyn A, Meriggioli MN, Shell R (2021) Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol 78:834–841
doi: 10.1001/jamaneurol.2021.1272
pubmed: 33999158
Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, Group ES (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723–1732
doi: 10.1056/NEJMoa1702752
pubmed: 29091570